G-Protein Coupled Receptors Global Market Report 2024

The g-protein coupled receptors market size has grown strongly in recent years. It will grow from $2.97 billion in 2023 to $3.18 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The expansion observed in the historical period can be credited to progress in drug discovery, FDA approvals, genomic breakthroughs, the emergence of new markets, consolidation within the market, and the increasing aging population.

The g-protein coupled receptors market size is expected to see strong growth in the next few years. It will grow to $4.09 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated expansion in the forecast period can be ascribed to personalized medicine, heightened emphasis on rare diseases, the integration of artificial intelligence in drug discovery, drug development centered around patients, considerations of environmental and social factors, and the burgeoning biosimilar market. Noteworthy trends expected in the forecast period encompass progress in biotechnology, augmented investment in research and development, technological innovations, collaborative initiatives and partnerships, as well as the growth of digital therapeutics.

The anticipated increase in the prevalence of cancer is expected to drive the expansion of the G-protein-coupled receptors market in the future. Cancer, characterized by the uncontrolled spread of abnormal cells, can invade surrounding tissues and utilize the lymphatic and vascular systems for dissemination. GPCRs play a crucial role in processes associated with cancer, such as proliferative signaling, replicative immortality, evasion of growth suppressors, resistance to apoptosis, and the activation of invasion and metastasis. For instance, in March 2023, the American Society of Clinical Oncology (ASCO) reported that 81,800 individuals in the United States are expected to be diagnosed with kidney cancer in 2023. Additionally, breast cancer surpassed lung cancer as the most commonly diagnosed cancer globally in April 2022, affecting an estimated 2.3 million women in 2021 alone, as per the Breast Cancer Research Foundation. In the United States, where breast cancer has been the most prevalent for years, 281,550 women are projected to be diagnosed in 2021. Consequently, the increasing prevalence of cancer is a key driver for the growth of the G-protein-coupled receptors market.

Rising healthcare expenditures are poised to fuel the expansion of the g-protein-coupled receptors (GPCR) market. Healthcare expenditures encompass the overall financial outlay on healthcare-related services, products, and activities over a specified period, be it at an individual, community, national, or global level. The surge in healthcare spending typically results in the proliferation of healthcare services and infrastructure. Consequently, there is an increased demand for drugs targeting GPCRs as healthcare providers seek advanced and innovative treatments to address a wide array of diseases and conditions. As an illustration of this trend, in May 2023, the Office for National Statistics, a reputable UK-based statistics authority, disclosed a notable uptick in healthcare spending in the United Kingdom. The report indicated a 9.4% nominal and 9.7% real-term increase in healthcare spending. In 2021, the total healthcare expenditure in the UK amounted to $367.25 billion (£280.7 billion), with pharmaceutical expenditure reaching $51.84 billion (£39.6 billion). Notably, preventive care spending surged to $45.93 billion (£35.1 billion) in 2021, more than doubling from the previous year. Thus, the escalating healthcare expenditure trajectory is anticipated to be a key driver for the g-protein-coupled receptors market, reflecting the growing emphasis on advanced therapeutic solutions within the healthcare landscape.

A prominent trend gaining traction in the G-protein-coupled receptor (GPCR) market is the strategic investment to advance GPCR screening and antibody development. Leading companies in the GPCR sector are actively seeking investments to propel the development of drugs and medication technologies associated with GPCR-related diseases. For example, in February 2023, LifeArc Ventures, a venture capital firm based in the UK, invested $16 million in Maxion Therapeutics, a UK-based drug discovery company. This investment aims to advance antibody development for previously untreatable ion channel and GPCR-driven disorders, leveraging the proprietary KnotBody technology for the development of antibody therapeutics targeting ion channels and GPCRs.

Major players in the G-protein-coupled receptor market are concentrating on the development of innovative assay kits to further therapeutic discovery related to GPCRs. Assay kits, comprised of reagents and materials for specific analytical procedures or tests, are pivotal in this pursuit. In January 2021, PerkinElmer Inc., a US-based healthcare corporation, introduced new assays, including the industry's first TR-FRET-based assay for GTP binding and kits for B-Arrestin 1, B-Arrestin 2, and AP2. These assays empower researchers to utilize preferred cell models, facilitating a better understanding of GPCRs' crucial role in disease through the study of interaction, expression, and potential modulation of intracellular proteins involved in GPCR signaling mechanisms.

In February 2021, Eurofins Scientific, a France-based bioanalytical testing company, acquired Beacon Discovery for an undisclosed amount. This acquisition broadens Eurofins Scientific's product portfolio, incorporating validated ADMET, in vitro pharmacology, and chemistry services for integrated drug discovery solutions. The move aligns with Eurofins' strategy to collaborate with the pharmaceutical industry, providing expertise, drug discovery experience, and a track record of success in facilitating the discovery and development of new therapeutics. Beacon Discovery, the US-based biotechnology company acquired by Eurofins Scientific, specializes in G-protein-coupled receptor (GPCR) research.

Major companies operating in the g-protein coupled receptors market report are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Danaher Corporation, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Thermo Fisher Scientific Inc., Perkin Elmer Inc., Qiagen N.V., Bio-Techne Corporation, Abcam PLC, Cara Therapeutics Inc., Sosei Heptares Ltd., Eurofins DiscoverX Corporation, Crinetics Pharmaceuticals Inc., Domain Therapeutics SA, Addex Pharmaceuticals Ltd., Escient Pharmaceuticals Inc., Structure Therapeutics, Septerna.

North America was the largest region in the G-protein coupled receptors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g-protein coupled receptors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the g-protein coupled receptors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main offerings associated with G-protein-coupled receptors include cell lines, detection kits, cell culture reagents, and ligands. A cell line refers to a selected uniform cell culture derived from a population of cells typically sourced from a homogeneous tissue. Various types of assays, including camp functional assays, calcium functional assays, β-arrestin functional assays, radioligand binding and GTPγS functional assays, internalization assays, and trafficking assays, are employed in diverse applications. These applications span areas such as cancer research, CNS research, metabolic research, cardiovascular research, inflammation research, respiratory research, and others.

The G-protein-coupled receptors market research report is one of a series of new reports that provides G-protein-coupled receptors market statistics, including the G-protein-coupled receptors industry global market size, regional shares, competitors with a G-protein-coupled receptors market share, detailed G-protein-coupled receptors market segments, G-protein-coupled receptors market trends, and opportunities, and any further data you may need to thrive in the G-protein-coupled receptors industry. This G-protein-coupled receptors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The G-protein-coupled receptors market consists of revenues earned by entities by providing GPCR screening and profiling services, GPCR antibodies and immunoassays, hormones visual control. The market value includes the value of related goods sold by the service provider or included within the service offering. The G-protein-coupled receptors market also includes sales of adenosine, serotonin, and metabotropic receptor. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.